Navigation Links
Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations

FRANKFURT, Germany, February 25 /PRNewswire/ -- t2cure, a clinical stage biopharmaceutical company developing novel regenerative therapies based on autologous progenitor cells, announced today that it has appointed Dr. Petra Rueck Head of Clinical Operations.

"We are pleased to have Petra join our company", said Manfred Ruediger, CEO of t2cure. "Petra's experience in clinical research and project management will be of critical importance to t2cure as we are preparing to move our lead product into Phase III clinical trials for severe infarcts."

"It is a unique opportunity to contribute to the development of therapies that have the potential to significantly improve patient outcomes", said Petra Rueck. "t2cure's clinical candidates have demonstrated their capacity to increase the regenerative potential of tissue damaged by acute myocardial infarctions and other cardiac or peripheral vascular diseases."

Prior to joining t2cure, Dr Rueck was a project leader with ratiopharm's Biogenerix AG, Mannheim, where most recently she was responsible for a biotechnology project including the design and management of preclinical and clinical development programs. Her previous experience includes positions in clinical research management at Pfizer and Intervet. Before that, Dr. Rueck was assistant professor at Berlin University Hospital "Benjamin Franklin" (now Charite) and worked as postdoctoral researcher at INSERM, Paris. Petra Rueck received her PhD degree in pharmacology from the University of Giessen, Germany, where she studied veterinary medicine.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy). The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and will enter Phase III soon. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.


Manfred Ruediger, CEO

t2cure GmbH

Bettinastrasse 35-37

D-60325 Frankfurt am Main

Tel: +49-69-75-61-46-87-0

Fax: +49-69-75-61-46-87-9


SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
2. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
3. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
4. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
5. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
6. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
7. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
8. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
10. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
11. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Matthew “Tex” ... new post, VerMilyea will oversee all IVF lab procedures as well as ... fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to bring home ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... of a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The ... available, and is operated by a world-class team of qualified medical researchers and ...
(Date:11/30/2015)... Partnership includes an MPP ... for the u niversity , s Solid ... s cale - up through ... Africa , where licensees based anywhere in the world will have the ... --> Africa , where licensees based anywhere in the world will ...
(Date:11/30/2015)... 30, 2015 Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... initiatives designed to create shareholder value. ... Spherix. "Based on published reports, the total addressable ... billion and Spherix will seek to secure fair ...
Breaking Biology Technology:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/18/2015)... November 18, 2015 --> ... a new market report titled  Gesture Recognition Market - ... 2015 - 2021. According to the report, the global gesture recognition ... anticipated to reach US$29.1 bn by 2021, at a ... North America dominated the global gesture ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
Breaking Biology News(10 mins):